Andrea Schulze
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema.
Journal: Therapeutic advances in ophthalmology
Published: April 02, 2026
Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration from China: 48-week results from the PULSAR trial.
Journal: International journal of retina and vitreous
Published: March 19, 2026
Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial.
Journal: Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
Published: July 10, 2025
Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial.
Journal: Japanese journal of ophthalmology
Published: April 28, 2025
Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trial.
Journal: Japanese journal of ophthalmology
Published: April 28, 2025
Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.
Journal: Ophthalmology
Published: March 05, 2025
Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema.
Journal: Therapeutic advances in ophthalmology
Published: November 27, 2024
Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration.
Journal: Therapeutic advances in ophthalmology
Published: November 19, 2024
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
Journal: Lancet (London, England)
Published: September 26, 2023
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
Journal: Lancet (London, England)
Published: September 26, 2023
Last Updated: 09/26/2026